
Pharma & Biotech
Medicines, side effects, generics, reimbursement — DOCTOR PHARMA guides you through the Belgian pharmaceutical world.
Belgian pharmaceutical, biotech and medicines regulation expert. Tone: scientific, rigorous, accessible. Masters FAMHP regulation, marketing authorizations (MA), pharmacovigilance, clinical trials, medical devices, NIHDI reimbursement and biotech specifics. Deep knowledge of Belgian federal framework and European regulation (EMA).
// SOUL.md
Ultra-specialized agent in pharma & biotech · 13 sub-domains of expertise · Tailored for individuals · Exclusive Belgian market · Available in French, Dutch, English and German
Expertise
DOCTOR PHARMA masters every aspect of their domain to provide you with precise advice tailored to the Belgian framework.
Marketing authorization (national, MRP, DCP, EMA centralized), CTD/eCTD dossier, variations, renewals, generics (bioequivalence)
Federal Agency for Medicines and Health Products, GMP inspections, manufacturing/distribution authorizations, import/export, narcotics/psychotropics
QPPV, adverse reaction reporting, PSMF, PSUR/PBRER, safety signals, risk management plans (RMP)
EU Regulation 536/2014, CTIS, Ethics Committee, informed consent, GCP, SUSAR, clinical trial insurance
MDR 2017/745, IVDR 2017/746, CE marking, classification (I/IIa/IIb/III), notified body, EUDAMED, post-market surveillance
Drug Reimbursement Committee (CRM), chapter IV, forms, maximum price, article 81 conventions, managed entry agreements
Pharmacy opening/transfer (moratorium), GPP (Good Pharmaceutical Practices), magistral/officinal preparations, hospital pharmacy, duty
Biosimilars, advanced therapies (ATMP), orphan drugs, biological production, cold chain, GDP
Medicine advertising (Book V ELC + RD 07/04/1995), medical visits, samples, MDEON (mandatory visa), transparency of advantages
Legal framework for medical cannabis in Belgium, special FAMHP authorizations, narcotics (1961 convention), psychotropics
EC Regulation 1223/2009 cosmetics, CPNP notification, food supplements (RD 03/03/1992), novel food, health claims
Pharma patents, SPC (Supplementary Protection Certificate), data exclusivity (8+2+1), Bolar exemption, generics litigation
BIM/OMNIO status, maximum billing (MAF), third-party payment, NIHDI reimbursement categories (A/B/C/Cs), co-payment, global medical record, Belgian patient rights
Use cases
Practical solutions for individuals
Understand and report an adverse drug reaction
Understand the difference and bioequivalence of generics
Check if a medicine is reimbursed by the health fund/NIHDI
Rules for buying over-the-counter medicines in Belgium
Legal framework for medical cannabis in Belgium
Find the duty pharmacy and understand the on-call system
Popular questions
FAQ
DOCTOR PHARMA is an AI consultant specialized in pharma & biotech for the Belgian market. It masters 13 sub-domains of expertise and can help you with: ma & registration, famhp regulation, pharmacovigilance, clinical trials, medical devices, and much more.
No, DOCTOR PHARMA is a decision-support tool. It provides analyses, template documents and advice based on Belgian law, but always recommends validation by a certified professional for important decisions.
Create a free account on KonsultIA.be, select DOCTOR PHARMA from the dashboard, and ask your question. The agent responds with precise information tailored to the Belgian context.
Yes, DOCTOR PHARMA is specifically trained on the Belgian legal and regulatory framework. It knows the specificities of the three regions (Brussels, Wallonia, Flanders) and cites reference texts.

Free trial · No credit card required · Instant answers